A Massachusetts startup advances scalable light-control tech for AR, AI and imaging markets
Updated
February 27, 2026 3:59 PM
Myrias Optics' Nanoimprinted All-inorganic Metaoptic. PHOTO: MYRIAS OPTICS
Myrias Optics, a Massachusetts-based optical technology startup, has raised US$2.1 million in a Seed 1 financing round to accelerate the commercialization of its advanced light-control technology. The round was led by MassVentures, with participation from existing investors Hoss Investment Inc., Maroon Venture Partners and Tenon Venture Partners, as well as new investors Mill Town Capital, TiE Boston Angels and Doug Crane. This new round follows a US$3.3 million seed financing completed in December 2023, led by Asia Optical, and a US$1.5 million Direct-to-Phase II award from the National Science Foundation. In total, Myrias has secured US$6.9 million to date, positioning it to move from development to scaled production.
The company builds ultra-thin, nano-patterned surfaces that precisely control how light moves through a device. These structures replace or enhance traditional lenses and optical parts inside products such as augmented reality headsets, AI data center hardware, consumer electronics, industrial systems and medical imaging devices. The goal is straightforward: to deliver high optical performance while making the parts easier and more cost-effective to manufacture in large quantities.
Across industries such as augmented reality and AI infrastructure, manufacturers face a common challenge. They need highly precise light-guiding components that can withstand heat and long-term use. At the same time, those components must be produced consistently and at scale. Traditional semiconductor-style fabrication can be costly, while polymer-based optical manufacturing can face limits in durability and thermal stability.
Myrias addresses this gap by using inorganic materials and a nanoimprint manufacturing process to create stable, repeatable optical layers on wafers. This approach is designed to combine performance with manufacturability. In augmented reality systems, for example, the company’s technology enables higher viewing angles while remaining suitable for volume production. In AI data centers, the same material and process advantages support improved light transfer and stronger performance under demanding thermal conditions. These benefits also extend to advanced imaging systems in consumer, industrial and medical markets.
The new Seed 1 funding is intended to expand manufacturing capacity and scale pilot production lines. The company will also continue executing active customer programs. Myrias is already working with strategic partners and Tier 1 supply chain participants to integrate its waveguide and light-shaping solutions into commercial AR platforms, AI photonics systems and advanced imaging products. The capital, therefore, supports a clear next step: moving from validated prototypes to a steady commercial supply.
Keep Reading
A new bet on early heart failure detection and why women’s health is at the center.
Updated
January 8, 2026 6:28 PM
A doctor holding an artificial heart model. PHOTO: ADOBE STOCK
Heart disease does not always announce itself clearly, especially in women. Many of the symptoms are ordinary, including fatigue, shortness of breath and swelling. These signs are frequently dismissed or explained away. As a result, many women are diagnosed late, when treatment options are narrower and outcomes are worse. That diagnostic gap is the context behind a recent investment involving Ultromics and the American Heart Association’s Go Red for Women Venture Fund.
Ultromics is a health technology company that uses artificial intelligence to help doctors spot early signs of heart failure from routine heart scans. It has received a strategic investment from the American Heart Association’s Go Red for Women Venture Fund.
The focus of the investment is a long-standing blind spot in cardiac care. Heart failure with preserved ejection fraction, or HFpEF, affects millions of people worldwide, with women disproportionately impacted. It is one of the most common forms of heart failure, yet also one of the hardest to diagnose. Studies even show women are twice as likely as men to develop the condition and around 64% of cases go undiagnosed in routine clinical practice.
Ultromics works with a tool most patients already experience during heart care: the echocardiogram. There is no new scan and no added burden for patients. Its software analyzes standard heart ultrasound images and looks for subtle patterns that point to early heart failure. The goal is clarity. Give clinicians better signals earlier, before the disease advances.
“Heart failure with preserved ejection fraction is one of the most complex and overlooked diseases in cardiology. For too long, clinicians have been expected to diagnose it using tools that weren't built to detect it and as a result, many patients are identified too late,” said Ross Upton, PhD, CEO and Founder of Ultromics. “By augmenting physicians' decision making with EchoGo, we can help them recognize disease at an earlier stage and treat it more effectively.”
The stakes are high. Research suggests women are twice as likely as men to develop the condition and that a majority of cases are missed in routine clinical practice. That delay matters. New therapies can reduce hospitalizations and improve survival, but only if patients are diagnosed in time.
This is why early detection has become a priority for mission-driven investors. “Closing the diagnostic gap by recognizing disease before irreversible damage occurs is critical to improving health for women—and everyone,” said Tracy Warren, Senior Managing Director, Go Red for Women Venture Fund. “We are gratified to see technologies, such as this one, that are accepted by leading institutions as advances in the field of cardiovascular diagnostics. That's the kind of progress our fund was created to accelerate.”
Ultromics’ platform is already cleared by regulators for clinical use and is being deployed in hospitals across the US and UK. The company says its technology has analyzed hundreds of thousands of heart scans, helping clinicians reach clearer conclusions when traditional methods fall short.
Taken together, the investment reflects a broader shift in healthcare. Attention is shifting earlier—toward detection instead of reaction. Toward tools that fit into existing care rather than complicate it. In this case, the funding is not about introducing something new into the system. It is about seeing what has long been missed—and doing so in time.